Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...

Novo Nordisk has been one of the chief beneficiaries ... build on the success of flagship weight-loss treatments Wegovy and Ozempic. Like those injections, the new drug targets gut hormone GLP ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide ... ZLDPF), Terns Pharmaceuticals (TERN) and Structure Therapeutics (GPCR).

Novo Nordisk reported that full-year sales of all its drugs grew 26% to $40.5 billion. However, the company projects that sales growth in 2025 will slowdown to between 16% and 24%. Ozempic and ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...